Innovations and Challenges in Melanoma
First Cambridge Conference - July 2005
This program was based on a conference of multidisciplinary leaders in melanoma research and clinical care. The focus of the program was on new perspectives on the epidemiology, biology and pathology of melanoma; new data and perspectives on staging and local/ regional therapies; new approaches to adjuvant therapy/vaccines/ immune monitoring; new approaches to immunotherapy for advanced disease; and new molecularly-targeted therapies for advanced disease. The program developed content for a peer reviewed educational publication for oncologists and other health care professionals who wish to expand their understanding of new approaches to assessing and treating melanoma.
The program was directed by Michael B. Atkins, MD , Director, Cutaneous Oncology and Biological Therapy Programs, Beth Israel Deaconess Medical Center.
Educational Objectives
1) Discuss new perspectives on the epidemiology, biology and pathology of melanoma; 2) discuss new data and perspectives on staging and local/regional therapies; 3) assess new approaches to adjuvant therapy/vaccines/immune monitoring; 4) assess new approaches to immunotherapy for advanced disease; and 5) assess new molecularly-targeted therapies for advanced disease.
Educational Grant Support
The program was supported by educational grants provided by: Chiron Corporation, Schering Plough, Berlex, Pfizer, Antigenics, Bayer Pharmaceuticals, Serono and CancerVax, Medarex, and 3M Pharmaceuticals.
Sponsorship
Program management, CME sponsorship and editorial assistance were provided by InforMEDical.
The conference proceedings were published as a peer-reviewed CME supplement to Clinical Cancer Research, Vol 12 (7 Suppl), April 2006.
The CME activity was effective April 2006 through March 2008.
